According to the Associated Press, a long-delayed blood thinner from AstraZeneca PLC won U.S. approval Wednesday, posing new competition to the multibillion-dollar blockbuster pill Plavix. The Food and Drug Administration said it approved Brilinta to reduce heart attacks and prevent deaths in patients with acute coronary syndrome, or clogged arteries. More than 1 million U.S. patients are hospitalized each year with heart attacks, stroke and other complications of the condition, according to the American Heart Association. The drug works by preventing the formation of blood clots that can block blood flow to the heart. The twice-a-day tablet is designed to be used in combination with low doses of aspirin. Twice last year, in September and December, the FDA delayed making a decision on the drug, which already is available in Europe and Canada.